Eli Lilly Canada Inc. v. Novopharm Limited, 2009 FC 1018 (Olanzapine*)
Justice O'Reilly - 2009-10-05
Read full decision. Automatically generated summary:
The plaintiffs are suing Novopharm for infringement of a patent for a medicine called olanzapine. Its brand name is Zyprexa. Olanzapine is regarded as a relatively safe, and often effective, medicine for treating schizophrenia. Olanzapine is widely prescribed and is a commercial success. It is the subject of a Canadian patent (No. 2,041,113) that I will refer to as the '113 patent. I will refer to the plaintiffs collectively as "Lilly". Lilly applied for the '113 patent in 1991 and was granted it in 1998.
Decision relates to:
- T-1048-07 - ELI LILLY CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-454-09(2010 FCA 130) - which is an appeal from this decision
- T-1048-07 - ELI LILLY CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-454-09(2010 FCA 197) - which is an appeal from this decision
- T-1048-07 - ELI LILLY CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-454-09(2010 FCA 219) - which is an appeal from this decision